Evidence map›Paper›PMID 37934389›Full record

ArticleMolecular biotechnology2024

The Potential of Circulating miR-193b, miR-146b-3p and miR-483-3p as Noninvasive Biomarkers in Cutaneous Melanoma Patients.

Atefeh Mohammadloo, Yazdan Asgari, Aghil Esmaeili-Bandboni, Mohammad Ali Mazloomi, Seyedeh Fatemeh Ghasemi, Sima Ameri, Seyed Rouhollah Miri, Shahin Hamzelou, Hamid Reza Mahmoudi, Ziba Veisi-Malekshahi

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Atefeh MohammadlooDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Yazdan AsgariDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Aghil Esmaeili-BandboniDepartment of Medical Biotechnology, School of Paramedical Sciences, Guilan University of Medical Sciences, Rasht, Iran.
Mohammad Ali MazloomiDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Seyedeh Fatemeh GhasemiDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Sima AmeriDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Seyed Rouhollah MiriCancer Research Center, Cancer Institute of Iran, Tehran University of Medical Science, Tehran, Iran.
Shahin HamzelouDepartment of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Hamid Reza MahmoudiAutoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Ziba Veisi-MalekshahiDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. zvmalekshahi@yahoo.com.ORCID http://orcid.org/0009-0008-1287-7877

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma is a destructive skin disease with few therapeutic options in the developed stage and therefore there is a critical need for reliable biomarkers for early diagnosis. In this context, microRNAs could play an important role as diagnostic biomarkers. Three datasets with accession numbers GSE31568, GSE61741 and GSE20994 were downloaded from the Gene Expression Omnibus (GEO) database. MATLAB software was used to analyze differentially expressed miRNAs between cutaneous melanoma plasma samples and normal plasma samples (control). Plasma levels of miR-193b, miR-146b-3p and miR-483-3p were evaluated by the RT-PCR method. Furthermore, linear regression followed by receiver operating characteristic analyses was performed to estimate whether selected plasma miRNAs were able to distinguish between cases and controls. Finally, the data were analyzed by unpaired Mann-Whitney U test using Graph pad prism 8 computer software. Specifically, miR-193b and miR-146b-3p were downregulated in the plasma of melanoma patients compared with control groups which were decreased 5 ×

Indexed as

Biomarkers, TumorGene Expression Regulation, NeoplasticMelanomaMicroRNAsSkin NeoplasmsCase-Control StudiesCirculating MicroRNACutaneous Malignant MelanomaGene Expression ProfilingHumansROC CurveBiomarkers, TumorCirculating MicroRNAMicroRNAsMIRN146 microRNA, humanMIRN193 microRNA, humanMIRN483 microRNA, humanBiomarkerDiagnosisMelanomaMiRNAPlasmaSystem biology

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.